The DOI matches its Crossref record.
LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Results from Phase III TROPION-Breast01 and TROPION-Lung01 trials demonstrated greater progression-free survival on Dato-DXd compared to standard-of-care therapy, leading to FDA approval of Dato-DXd in metastatic HR+/HER2- breast cancer and EGFR+ NSCLC.
“Results from the Phase III TROPION-Breast01 and TROPION-Lung01trials demonstrated greater progression-free survival on Dato-DXd compared to standard-of-care therapy, leading to the FDA approval of Dato-DXd in metastatic HR + /HER2– breast cancer and EGFR + NSCLC135,136.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [135]
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sorted by citations
The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer
Lin, C., Hadfield, M. J., Santopietro, A., Lagos, G., Cheng, L., El-Deiry, W. S., Aggarwal, R., Mega, A., Hyams, E., & Carneiro, B. A. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01131-0 · Cited by 20
Wang, J., Tong, Z., Tan, Y., Shi, Y., Wu, Y., Zhou, Q., Xing, X., Chen, X., Qiu, F., & Ma, F. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101707 · Cited by 16
Metadata
- Authors
- Bardia, A., Jhaveri, K., Im, S.-A., Pernas Simon, S., De Laurentiis, M., Wang, S., Martinez, N., Santos Borges, G., Cescon, D. W., Hattori, M., Lu, Y.-S., Hamilton, E. P., Zhang, Q. Y., Tsurutani, J., Kalinsky, K., Xu, L., Denduluri, N., Rugo, H. S., Xu, B., & Pistilli, B.
- Affiliations
- Massachusetts General Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- Seoul National University (KR)
- Sun Yat-sen University (CN)
- University Health Network (CA)
- Aichi Cancer Center (JP)
- National Taiwan University (TW)
- Tennessee Oncology (US)
- Third Affiliated Hospital of Harbin Medical University (CN)
- SHOWA Medical University (JP)
- Winship Cancer Institute (US)
- University of California, San Francisco (US)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Institut Gustave Roussy (FR)
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2023-10
- Volume
- 34
- Pages
- S1264-S1265
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4387809675
- Cited by
- 43
- References
- 0
- Citations by year
- 2026: 2 · 2025: 12 · 2024: 28 · 2023: 1
- Type
- conference abstract
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Funders
- Pfizer
- Sanofi
- Gilead Sciences
- Clovis Oncology
- Radius Health
- Jounce Therapeutics
- Daiichi-Sankyo
- Eisai
- MedImmune
- Genentech
- Loxo Oncology
- Foundation Medicine
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- datopotamab deruxtecan, antibody-drug conjugates, TROP2, hormone receptor-positive breast cancer, HER2-negative breast cancer, metastatic breast cancer, inoperable breast cancer, previously treated patients, progression-free survival, chemotherapy comparison
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
